This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Karim, M Y Articles by Abbs, I C Search for Related Content PubMed PubMed Citation Articles by Karim, M Y Articles by Abbs, I C Social Bookmarking                         What's this?

Mycophenolate mofetil in nonlupus glomerulonephropathy

Frimley Park and Royal Surrey County Hospitals, Guy’s and St Thomas’ NHS Foundation Trust

I C Abbs

Guy’s and St Thomas’ NHS Foundation Trust

Mycophenolate mofetil (MMF) initially found widespread use in the immunoprophylaxis of rejection in organ transplantation. It has subsequently been used in lupus glomerulonephritis, where early studies have shown it to be effective in induction and maintenance therapy. The randomized studies have mostly studied small groups of patients and their conclusions do need to be confirmed in larger studies. MMF has also been used in small numbers of patients in a variety of nonlupus glomerulopathies, which have different underlying immunopathology as well as clinical course, including IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, hepatitis-C-associated glomerulonephritis and even Goodpasture’s syndrome. In this article, we discuss its use in such nonlupus glomerular diseases.

Key Words: FSGS • glomerulopathy • IgA nephropathy • membranoproliferative • membranous • mesangiocapillary • mycophenolate

Lupus, Vol. 14, No. 3 suppl, s39-s41 (2005)
DOI: 10.1191/0961203305lu2116oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?